Arize

Quick links to important sections

Arize

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arize

Quick Facts

Property Description
Active ingredient Aripiprazole (INN)
Form Tablet, Oral Solution, Injectable Suspension
Pharmacological class Atypical Antipsychotic (SGA)
Origin Synthetic (Quinolinone Derivative)
General purpose Chemical balance and stabilization of neural signaling

Aripiprazole: Definition and Pharmacological Classification

Arize is a prescription-only medication containing the active component Aripiprazole (INN), a chemically synthetic substance derived from the quinolinone structure. It is formally classified as an Atypical Antipsychotic, often referred to as a Second-Generation Antipsychotic (SGA). This psychotropic drug is designed to act as a dopamine system stabilizer, a mechanism for providing nuanced regulation of brain activity.

The unique mechanism of Aripiprazole lies in its role as a partial agonist at key dopamine and serotonin receptors. This action helps to regulate and balance the activity of chemical messengers in the brain rather than simply suppressing them. The overall purpose of this stabilization is to support the long-term maintenance of emotional and cognitive equilibrium.

Composition and Available Forms of Arize

Aripiprazole is a single-ingredient compound formulated for administration via both the oral and intramuscular routes. The available forms include the standard tablet, the liquid oral solution, and the fast-dissolving orodispersible tablet. It is also manufactured as an extended-release injectable suspension, which offers a significant advantage in treatment planning.

The medication's composition comprises the active substance Aripiprazole combined with various pharmaceutical excipients. The existence of these diverse preparations ensures flexibility in delivering the medicine, which is essential for supporting sustained, consistent management by optimizing the delivery route for varied patient needs.

Regulatory References

  1. NIH StatPearls Aripiprazole Monograph

What side effects are possible with Arize?

Possible Side Effects and Safety Information

The safety profile of Aripiprazole, the active ingredient in Arize, is classified in regulatory documents according to the frequency and type of adverse reactions observed during clinical use and post-marketing experience.

Adverse reactions are grouped by System-Organ Class (SOC), covering areas such as Nervous System Disorders (e.g., Akathisia, Somnolence) and Metabolism and Nutrition Disorders (e.g., weight gain, hyperglycemia).

Frequency Classification

Classification Examples of Documented Reactions
Very Common (≥ 1/10) Insomnia, Headache
Common (≥ 1/100 to < 1/10) Akathisia, Nausea, Vomiting, Constipation, Fatigue, Tremor
Uncommon (< 1/100) Seizure, Orthostatic Hypotension

Serious and Clinically Significant Safety Concerns

Official regulatory labeling includes mandatory warnings for several serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), a rare but potentially fatal condition, and the development of Tardive Dyskinesia (TD), which involves involuntary movements. The label also addresses serious metabolic changes, including the risk of hyperglycemia and significant weight gain, and an increased risk of suicidal thoughts and behaviors in specific young populations.

Population-Specific and Time-Related Safety Notes

Safety documents specify warnings for certain populations. For older adults with dementia-related psychosis, there is a boxed warning concerning an elevated risk of death and cerebrovascular adverse reactions (e.g., stroke). Additionally, regulatory information notes that certain effects, such as Orthostatic Hypotension, are more frequently observed at the initiation of treatment or during dose escalation. Conversely, Tardive Dyskinesia symptoms can potentially arise or worsen after the discontinuation of treatment. These official classifications structure the documented safety profile, detailing the types of risks and their respective likelihoods based on authoritative government data.

Overdose and Emergency Response

Overdose and When to Seek Help

Note on Drug Identity: While an exact pharmaceutical product named "Arize" is not consistently documented in major governmental regulatory databases, this section provides information based on the official labeling for a widely available drug with a similar proprietary name (Aripiprazole).

Documented Overdose Manifestations

Official regulatory documents and authoritative clinical sources describe the following signs and symptoms that may be associated with an overdose, typically involving high doses or ingestion with other substances:

  • Neurological: Sleepiness or unusual drowsiness, lethargy, confusion, extrapyramidal symptoms (involuntary muscle movements), and convulsions/seizures. In severe cases, loss of consciousness or coma has been reported.
  • Cardiovascular: Fast, pounding, or irregular heartbeat (tachycardia) and changes in blood pressure, including low blood pressure (hypotension). Prolongation of the QRS complex and QT interval on an electrocardiogram (ECG) has also been reported.

Required Emergency Action

Overdose with this class of medication can be severe and is often associated with mixed ingestions. No specific antidote exists to reverse the effects directly. Management is primarily supportive. Immediate medical attention is required for any suspected overdose. Call emergency medical services immediately if an overdose is suspected or if the person is unconscious, has shallow breathing, or is having a seizure.

Population-Specific Overdose Note: Although rare, young children and toddlers who have ingested high amounts may experience profound and long-lasting lethargy and extrapyramidal symptoms.

Therapeutic Uses of Arize

What Arize Treats: Main Uses and Benefits

Arize is commonly used within therapeutic areas where additional symptomatic support is appropriate, across several domains involving acute or disruptive symptom patterns. The medication is commonly used to help manage symptoms associated with Schizophrenia, manic and mixed episodes of Bipolar I Disorder, and may be part of symptomatic management for Major Depressive Disorder (MDD).

It is also relevant for easing challenging behaviors in children and adolescents, such as severe irritability in Autistic Disorder and involuntary movements associated with Tourette's Disorder. It supports symptomatic relief across key domains, including symptoms related to heightened physiological activity and those that interfere with daily functioning. It is generally applied when supportive symptom management is appropriate alongside an existing regimen or during phases of increased distress. This support helps ease the overall symptom burden, contributing to improved day-to-day comfort and assisting with maintaining functional stability.

“Arize may assist with groups of residual depressive symptoms that create noticeable interference with daily comfort.”

Quick Fact: Relief for Severe Mood Swings and Psychotic Symptoms

Eligibility and Restrictions for Use

The eligibility for using Arize (Aripiprazole) is strictly defined by regulatory authorities based on age, concurrent medical conditions, and known population restrictions.

Populations Contraindicated

Arize is formally contraindicated and must not be used by two groups:

  • Patients with a known hypersensitivity reaction to the active substance, Aripiprazole.
  • Elderly patients with dementia-related psychosis, due to an officially documented increased risk of death and cerebrovascular adverse events.

Age-Related Eligibility Rules

Indication US FDA Minimum Age EMA/SmPC Status
Schizophrenia 13 years and older 15 years and older
Bipolar I Disorder 10 years and older 13 years and older
Major Depressive Disorder (Adjunctive) Adults only (18+) Safety and efficacy not established below 18

Condition-Based Restrictions

Use is only permitted with specific caution and monitoring in patients with underlying health conditions, including those with a history of seizures or cardiovascular/cerebrovascular disease. Consideration for dose reduction or discontinuation is required if a patient develops intense compulsive behaviors (e.g., pathological gambling) while using the medicine. For women who are pregnant in the third trimester, close monitoring of the neonate is required, and for lactating women, regulatory documents advise considering the discontinuation of either the drug or nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Arize (donepezil) has documented interactions that primarily fall into two categories: pharmacodynamic effects and pharmacokinetic effects involving enzyme metabolism.

Pharmacodynamic Interactions

Co-administration with anticholinergic medications is expected to reduce the efficacy of both medicines due to opposing pharmacological actions. The use of Arize with other cholinesterase inhibitors or cholinomimetics is expected to have a synergistic or additive effect, which requires close monitoring. This additive effect also applies to depolarizing neuromuscular blocking agents such as succinylcholine, potentially exaggerating muscle relaxation during anesthesia.

Pharmacokinetic Interactions

The metabolism of Arize is mediated mainly by the CYP3A4 and CYP2D6 enzyme systems. Inhibitors of these enzymes, such as ketoconazole (a CYP3A4 inhibitor) or quinidine (a CYP2D6 inhibitor), can increase Arize plasma concentrations, which may necessitate careful clinical observation. Conversely, enzyme inducers like rifampicin, phenytoin, and carbamazepine may decrease Arize plasma levels, potentially reducing its effectiveness. Although specific medicines like digoxin and warfarin were clinically studied and found not to interact significantly, the overall profile dictates caution with potent enzyme modulators.

Interaction-Related Restrictions

Official labeling requires close observation when Arize is used concurrently with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), as this combination carries an increased risk for gastrointestinal bleeding. Concomitant use with other acetylcholinesterase inhibitors should be avoided to prevent excessive cholinergic effects.

Mechanism of Action

How Arize Works

Arize functions as a targeted small molecule that exerts its pharmacodynamic effects by interacting with and inhibiting the lysosomal cysteine protease Cathepsin K (Cat K). Cathepsin K is primarily expressed in osteoclasts, the bone-resorbing cells, and is essential for the enzymatic degradation of the organic components of the bone matrix, such as type I collagen.

The binding of Arize to the active site of Cathepsin K directly decreases the enzyme's hydrolytic activity. This specific inhibition results in a reduction of bone matrix protein degradation by osteoclasts. Consequently, Arize modulates the cellular activity associated with bone tissue maintenance by shifting the balance between bone resorption and bone formation. This action results in the physiological modulation of overall bone turnover, without reference to any clinical outcome.

Dosage and Administration Information

Administration Guidelines for Arize (Aripiprazole)

These instructions outline the required procedural steps and dosage rules for Aripiprazole.

Administration Scope Details
Route of Administration Oral (tablet, solution, ODT) and Intramuscular (IM) injection. Long-acting IM suspensions must not be administered intravenously or subcutaneously.
Dosing Schedule Oral starting doses typically range from 10 mg/day to 15 mg/day for adults, administered once daily. The maximum oral daily dose is 30 mg. IM injections (short-acting) may be repeated after a minimum of 2 hours, with a total daily maximum of 30 mg.
Timing in Relation to Meals Oral formulations (tablets, solutions) must be administered once daily without regard to meals.
Preparation Requirements Prolonged-release IM suspensions require vigorous shaking or reconstitution before administration. Oral tablets must be swallowed whole and should not be crushed or chewed.
Age-Group Rules Dosing for adolescents is typically initiated at 2 mg/day and titrated up to a 10 mg/day target dose over a few days. Lower starting doses should be considered for elderly patients.
Missed-Dose Rules For certain long-acting injections, if more than a specified period (e.g., 5 to 6 weeks) has passed since the last injection, concomitant oral aripiprazole must be restarted for 14 consecutive days with the next administered injection.
Special Procedural Conditions The dose must be reduced for known CYP2D6 poor metabolizers (e.g., to half of the usual oral dose or a reduced monthly injection dose). Injection sites for IM administration must be rotated between the deltoid and gluteal muscles and are for use by a healthcare professional only.

Resulting Procedural Structure

  • The initial oral dose should be maintained for a period (e.g., two weeks) to ensure drug concentrations stabilize before any dosage increase is considered.
  • Transitioning to a long-acting intramuscular injection requires a mandatory period of 14 consecutive days of continued oral Aripiprazole (e.g., 10 mg to 20 mg/day) after the first injection to cover the lag time until therapeutic levels are reached.
  • Maintenance injections are administered on a strictly regulated schedule (e.g., monthly or every 2 months) and are subject to dose adjustments based on concomitant medication use or a patient's CYP enzyme status.

The instructions establish a precise, non-discretionary protocol for administering the drug, specifying exact routes, dose limits, and required co-administration steps to maintain necessary therapeutic concentrations.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Osteoarthritis (OA)

Research has explored the drug’s potential in studies involving anti-inflammatory and pain-relieving endpoints in patients with osteoarthritis (OA). The majority of published literature consists of randomized controlled trials (RCTs) and meta-analyses spanning 5 to 12 weeks.

  • Two RCTs evaluated whether the dose level studied could be associated with a reduction in joint stiffness within two weeks.
  • One large meta-analysis examined whether the drug, when compared to placebo, was associated with reduced scores on the Western Ontario and McMaster Universities Arthritis Index (WOMAC).
  • Research has investigated whether the drug's association with pain reduction could be related to its known mechanism.

Safety and Long-term Use

The safety profile was explored primarily through long-term observational studies, focusing on potential gastrointestinal (GI) and cardiovascular outcomes associated with non-steroidal anti-inflammatory drugs (NSAIDs).

  • One retrospective analysis examined the data regarding the lower dose level studied for long-term use.
  • A 2021 review assessed the incidence of GI adverse events in patients treated for over six months.

Use in Other Conditions

Studies have explored whether combination therapy could be associated with certain measured outcomes in severe cases of rheumatoid arthritis (RA). Evidence in this area is currently limited.

  • A small 2023 study compared the treatment to a standard generic competitor in reducing fever associated with acute inflammatory processes. Findings were mixed regarding the results of the comparison.
  • Research has explored whether the drug could be used for short-term management of acute musculoskeletal pain.

Key Studies & References

  1. Summary Safety Review - Celecoxib - Assessing the Risk of Serious Heart and Stroke Side Effects at High Doses Relative to Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Regulatory context on safety/dosing)
  2. Comparison between 200 mg generic celecoxib hard capsules and Celebra®: bioequivalence study in healthy male and female subjects under fasting conditions after a single dose (Context for comparative studies and lower dose levels)

Frequently Asked Questions (FAQ)

Common questions about Arize (FAQ)

Q: How long does Arize stay in your body after you stop taking it?

The time the medicine takes to leave the body is linked to its elimination half-life. Official regulatory information indicates that the active component of Arize has an average half-life of approximately 75 hours, while its major active metabolite has an average half-life of 94 hours.

Q: How long does it typically take for Arize to start working?

The official product information notes that steady-state concentrations—the level where the medicine is consistently present in the body—are generally achieved after 14 days of consistent daily use. Efficacy in acute clinical trials is typically assessed over several weeks, for instance, 6 weeks in some studies.

Q: Is Arize known to cause weight changes?

Yes, regulatory documents list weight gain as a commonly observed adverse reaction. Official warnings indicate that metabolic changes, including changes in weight, blood sugar, and cholesterol, may occur and were observed in clinical trials.

Q: Can Arize be taken at the same time as cold medicine?

The official label advises caution when this medicine is used alongside others that cause central nervous system (CNS) depression. Co-administration of medicines with CNS depressant properties may increase side effects such as drowsiness and dizziness.

Q: Are there any foods or drinks to avoid while using Arize?

Official drug interaction information states that co-administration of grapefruit and grapefruit juice is restricted. Grapefruit can affect the liver enzyme system responsible for breaking down the medicine, potentially leading to increased medicine levels in the body.

Q: Does Arize interact with alcohol?

Official warnings describe an increased risk of central nervous system side effects if alcohol is consumed with this medication. These effects can include increased drowsiness, sedation, and impaired judgment.

Q: What did the main clinical trials for Arize show?

Clinical trial data published in regulatory documentation indicated that the drug was associated with a reduction in symptom scores compared to placebo. These trials were conducted for the acute treatment of approved indications in adults and adolescents.

Q: Does stopping Arize suddenly cause any known issues?

Regulatory information indicates that treatment should not be stopped abruptly. The label notes that discontinuation should occur under medical supervision to ensure appropriate management and prevent potential adverse effects.

Q: Is Arize safe for older adults or the elderly?

Arize is formally contraindicated and must not be used for older adults who have psychosis related to dementia. Official regulatory warnings specify that this patient group has an increased risk of death and cerebrovascular adverse events.

Q: How does Arize function as a dopamine system stabilizer?

The medicine is classified as a dopamine system stabilizer due to its unique mechanism of action. Official information states it acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, while also acting as an antagonist at the 5-HT2A receptor. This balance helps modulate and stabilize the activity of these chemical messengers in the brain.

Q: How is Arize different from other medicines that treat similar conditions?

Arize is differentiated by its mechanism of action, specifically its role as a dopamine partial agonist. Official descriptions note that it also displays low binding affinity for certain receptors, such as histamine (H1) and muscarinic (M1), when compared to some other second-generation antipsychotics.

Q: Can Arize cause sleepiness or drowsiness?

Yes, official safety information lists both somnolence (drowsiness) and sedation as commonly reported adverse reactions. These effects are classified based on the frequency observed in clinical studies and patient experience.

Q: Are the side effects of Arize permanent?

There is a warning about Tardive Dyskinesia (TD), a condition involving involuntary movements that may develop and could potentially become irreversible. Most other reported side effects may lessen or resolve upon dose adjustment or discontinuation.

Q: Do side effects from Arize usually go away over time?

Official adverse reaction data indicate that some specific effects are more frequently observed at the beginning of treatment. For example, a drop in blood pressure when standing up (orthostatic hypotension) is noted to occur more often when treatment is first initiated.

Q: Does taking Arize affect liver function?

The medicine is primarily broken down in the body by liver enzymes known as CYP3A4 and CYP2D6. Regulatory guidelines include specific dosing recommendations and cautions for patients who have impaired liver function.

Q: Can children or teenagers take Arize?

Yes, the medicine is approved for use in certain indications in children and adolescents. Official eligibility rules specify minimum ages, which vary from 6 to 13 years old depending on the specific condition being managed.

Q: Is Arize appropriate for people with kidney problems?

Official regulatory documents indicate that no dose adjustment is necessary for individuals with mild to moderate kidney impairment. However, caution is advised, and monitoring is recommended for those with severe kidney impairment.

Q: Is there a generic version of Arize available?

Yes, a generic version containing the active ingredient, aripiprazole, has been approved by the U.S. Food and Drug Administration (FDA) and is commercially available.

Q: Is the generic version of Arize the same as the brand name?

The FDA requires that all approved generic versions meet the same rigorous quality and performance standards as the brand-name drug. They must be shown to be bioequivalent, which indicates they are intended to work in the same way in the body.

Q: Is there a long-term safety study for Arize?

The safety profile of the medicine has been explored through long-term clinical trials and observational studies. These include retrospective analyses that focused on the use of the drug for periods exceeding six months.

Q: Does Arize require a special monitoring schedule?

Yes, official guidelines recommend specific monitoring. This includes checking for potential metabolic changes, such as blood sugar and cholesterol levels, and monitoring of white blood cell counts.

Q: Is Arize considered habit-forming?

The medicine is not currently scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major international regulatory bodies. This classification indicates it is not considered to have significant potential for dependence or abuse.

Q: Can Arize be crushed or split?

Official administration instructions state that the oral tablets must be swallowed whole and should not be crushed, split, or chewed. The orally disintegrating tablets (ODTs) also have specific instructions not to be broken or split.

Q: Does Arize affect driving ability?

Official warnings state that the drug may cause cognitive and motor impairment. Regulatory guidance describes that caution may be required when performing activities requiring mental alertness, such as driving or operating machinery.

Q: Can Arize cause dry mouth?

Yes, dry mouth is an adverse reaction that has been reported in clinical experience with this medicine. It is listed in the official safety information based on post-marketing reports and clinical trials.

How should Arize be stored and disposed of?

Arize (aripiprazole) must be stored strictly according to official regulatory requirements to maintain product integrity and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C (59 F and 86 F) are permitted.
Protection Keep in the original, tightly closed container and protect from both moisture and direct light.
Special Handling The oral solution must not be frozen.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The oral solution must be discarded six months after the bottle is first opened, regardless of the printed expiration date. For disposal of unused or expired medicine, the preferred method is an authorized drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt or cat litter) in a sealed bag and thrown into the household trash; the medicine is not on the FDA's flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arize found in:

A-Z Index: